-

Agilent Announces CrossLab Group Leadership Transition

Mark Doak to Retire May 1, Padraig McDonnell to lead Agilent CrossLab Group

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Mark Doak, Agilent senior vice president and president of the Agilent CrossLab Group, has decided to retire on May 1, 2020. The company has named Padraig McDonnell, currently vice president and general manager, Chemistries and Supplies Division, to succeed him. Doak will continue as an active member of the executive staff until his retirement date, working with McDonnell to ensure a smooth transition.

Mark Doak has had a successful 42-year career in the analytical and scientific-instrument industry. He started his career with Beckman Instruments and later joined Hewlett-Packard (Agilent’s predecessor) in 1982. During his tenure with Agilent, he has held various senior-management positions across marketing, quality and services. Doak has led the Agilent CrossLab Group since 2014.

“Mark has been a key contributor to Agilent’s success for many years,” said Mike McMullen, Agilent president and CEO. “His leadership, knowledge and drive have helped make Agilent the industry leader it is today. I personally want to thank Mark for all that he has done to help lead our company and wish him all the best in his retirement.

“I’m also extremely pleased that Padraig McDonnell has accepted the role of leading our CrossLab Group upon Mark’s retirement. His history as a key member of Mark’s team, combined with his broad-based experience, track record of results and outstanding leadership skills, make Padraig the ideal person to take on this assignment. I have the utmost confidence he will continue to produce the same high level of success that Mark has achieved.”

McDonnell has been with Agilent for 22 years and has served in a variety of key sales and business-unit leadership positions. Prior to his current role leading the Chemistries and Supplies Division for the past three years, McDonnell was the vice president and general manager of Agilent’s Life Science and Applied Markets Group for Europe, the Middle East and India.

“While I was conflicted about retiring, Agilent and the Agilent CrossLab Group are in a solid position to continue their positive growth trajectories and the timing was right from an organizational perspective,” Doak said. “I look forward to working closely with Padraig in the coming months to help ensure a seamless transition.”

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom.

Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

INVESTOR CONTACT:
Ankur Dhingra
+1 408-345-8948
ankur_dhingra@agilent.com

MEDIA CONTACT:
Tom Beermann
+1 408-553-2914
tom.beermann@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Summary
Agilent announces CrossLab Group leadership transition; Mark Doak to retire May 1. Padraig McDonnell selected as his replacement.
Release Versions
$Cashtags
Hashtags

Contacts

INVESTOR CONTACT:
Ankur Dhingra
+1 408-345-8948
ankur_dhingra@agilent.com

MEDIA CONTACT:
Tom Beermann
+1 408-553-2914
tom.beermann@agilent.com

More News From Agilent Technologies Inc.

Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company’s expanding capabilities across Canada and the United States. Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customizable manufacturing so...

Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions

SANTA CLARA, Calif. & SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million. Biocare is a high-growth global pathology antibody leader, serving customers with a complementary portfolio of immunohistochemistry (IHC), in sit...

Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% core(1) compared with the first quarter of 2025. First-quarter GAAP net income was $305 million, or $1.07 per share. This compares with $318 million, or $1.11 per share, in the first quarter of 2025. Non-GAAP(2) net income was $386 million, or $1.36 per share, during the quarter, compared wi...
Back to Newsroom